Invivyd's Stock Performance Gains Attention Invivyd (NASDAQ: IVVD) has seen a remarkable stock surge in 2025, driven by positive Phase 1/2 clinical trial results for VYD2311, a monoclonal antibody candidate. The treatment shows promise as a durable alternative to traditional COVID-19 vaccines. Meanwhile, PEMGARDA™ reported a 48% revenue increase in Q4 2024, underlining commercial success.12